Loading stock data…
BDRX
$3.03-0.13 (-4.11%)
Market ClosedLast close May 1
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Biodexa Pharmaceuticals Plc in the Healthcare sector is trading at $3.03. The stock is currently near its 52-week low of $2.86, remaining 85.4% below its 200-day moving average. Technical signals show neutral RSI of 49 and bullish MACD crossover, explaining why BDRX maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 49) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.03
Potential Upside
5%
Whystock Fair Value$3.18
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Mean target$36.03+1089.1%
Range$36.03 – $36.03
Fundamentals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.52M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.11
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-55.98%
Volume
Today's trading volume
16,613
Recent News
European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading; Gain 1.3% for Week
European equities traded in the US as American depositary receipts were trending marginally higher l
European Equities Traded in US as ADRs Ease in Thursday Trading
European equities traded in the US as American depositary receipts eased late Thursday morning with
European Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday Trading
European equities traded in the US as American depositary receipts were higher late Wednesday mornin
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday Trading
European equities traded in the US as American depositary receipts were falling sharply late Tuesday
European Equities Traded in the US as ADRs Rise in Tuesday Trading
European equities traded in the US as American depositary receipts rose late Tuesday morning with th